DEF: Theriva Biologics Seeks Shareholder Approval for Warrant Issuance

Theriva Biologics, Inc. is calling a Special Meeting of Stockholders on April 9, 2026, to approve the issuance of up to 16,184,560 common shares from warrant exercises and an adjournment proposal.

Summary

• A Special Meeting of Stockholders will be held on April 9, 2026, at 3:30 p.m. local time in Barcelona, Spain.
• The primary purpose is to approve the issuance of up to 16,184,560 shares of common stock upon the exercise of common stock purchase warrants issued to institutional investors in a private placement that closed on October 17, 2025 (the Warrant Exercise Proposal).
• The meeting will also seek approval for an Adjournment Proposal, allowing the meeting to be postponed if necessary to solicit further votes for the Warrant Exercise Proposal.
• The record date for stockholders entitled to vote is February 27, 2026.
• The New Warrants were issued as an inducement for institutional investors to immediately exercise previously issued 'Existing Warrants' (from private placements on September 27, 2024, and May 8, 2025) at a reduced exercise price of $0.54 per share.
• The New Warrants allow the purchase of shares equal to 200% of the number of Existing Warrant Shares issued upon exercise of the Existing Warrants, also at an exercise price of $0.54 per share.
• Stockholder approval is required under Section 713(a) of the NYSE American Company Guide because the issuance is greater than 20% of outstanding common stock and for less than the applicable Minimum Price.
• Previous special meetings scheduled for December 15, 2025, and February 11, 2026, failed to convene due to a lack of quorum.
• If approved, the company could receive up to approximately $8.7 million in gross proceeds from the exercise of the New Warrants.
• Failure to approve the Warrant Exercise Proposal would prevent the company from permitting the exercise of the New Warrants and would incur substantial additional costs for holding repeated stockholder meetings.
• The Board of Directors unanimously recommends voting FOR both the Warrant Exercise Proposal and the Adjournment Proposal.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a necessary but challenging capital-raising effort, marred by repeated failures to secure shareholder quorum and significant potential dilution, which could negatively impact existing shareholder value despite the potential for new funds.

Positives

• Potential to raise up to approximately $8.7 million in gross proceeds if the New Warrants are fully exercised for cash, which would strengthen the company's financial position.
• The inducement agreement successfully encouraged institutional investors to immediately exercise Existing Warrants, providing immediate cash flow to the company.
• The capital infusion is crucial for funding the company's ongoing operations, particularly in research and clinical development.

Negatives

• The issuance of up to 16,184,560 additional shares of common stock represents significant dilution for existing stockholders, given 45,892,668 shares were outstanding as of the record date.
• The potential sale of these newly issued shares into the public market could materially and adversely affect the market price of the company's common stock.
• The company has failed twice (on December 15, 2025, and February 11, 2026) to achieve a quorum for stockholder approval, indicating potential shareholder apathy or resistance to the proposal.
• Failure to obtain approval will result in substantial additional costs and expenses due to the obligation to hold further stockholder meetings every 60 days until approval is secured or the warrants expire.
• The exercise price of $0.54 per share for the New Warrants is below the closing price of $0.84 on October 15, 2025, suggesting a discounted offering that could be perceived negatively by existing shareholders.

Risks

• Failure to obtain stockholder approval for the Warrant Exercise Proposal means the company cannot permit the exercise of the New Warrants, leading to a loss of up to $8.7 million in potential gross proceeds.
• The company is obligated to incur substantial additional costs and expenses by holding repeated stockholder meetings every 60 days until approval is obtained or the New Warrants are no longer outstanding.
• Existing stockholders will suffer significant dilution in their ownership interests upon the issuance of up to 16,184,560 New Warrant Shares.
• The future sale of these New Warrant Shares into the public market could materially and adversely affect the market price of the company's common stock.
• There is a risk of continued failure to achieve a quorum at the Special Meeting, as experienced in previous attempts on December 15, 2025, and February 11, 2026.

Future Outlook

The company is obligated to continue calling special meetings every 60 days thereafter to seek stockholder approval for the Warrant Exercise Proposal until it is obtained or the New Warrants are no longer outstanding. The New Warrants are exercisable commencing on the effective date of stockholder approval and expire on the fifth anniversary of that date, indicating a long-term financing component contingent on shareholder action.

Management Comments

• "Your vote is very important. Whether or not you plan to attend the Special Meeting, we encourage you to read the accompanying Proxy Statement and to submit your proxy or voting instructions as soon as possible."
• "In order to ensure the representation of a quorum at the Special Meeting, stockholders who do not expect to attend the Special Meeting are urged to vote as soon as possible."
• "The Board of Directors believes that if at the Special Meeting, the number of votes represented by shares of our Common Stock, present or represented and voting in favor of the Warrant Exercise Proposal, is insufficient to approve the Warrant Exercise Proposal, it is in the best interests of the stockholders to enable the Board to continue to seek to obtain a sufficient number of additional votes to approve the Warrant Exercise Proposal."

Industry Context

StockSavvy.ai notes that companies in the biologics and pharmaceutical sector, like Theriva Biologics, frequently rely on capital raises, including warrant exercises and private placements, to fund extensive research and development, clinical trials, and operational expenses. The requirement for shareholder approval for significant equity issuances below market price is a standard NYSE American mandate, designed to protect existing shareholders from excessive dilution without their explicit consent. The repeated failure to achieve a quorum for this approval suggests potential challenges in shareholder engagement or underlying concerns among investors regarding the terms of the capital raise or the company's strategic direction.

Comparison to Industry Standards

• The requirement for shareholder approval for equity issuances exceeding 20% of outstanding shares or below a 'Minimum Price' is a standard corporate governance practice for NYSE American listed companies, as per Section 713(a) of the NYSE American Company Guide. This aligns with broader industry standards aimed at protecting existing shareholders from significant dilution without their consent.
• The exercise price of $0.54 per share for the New Warrants, while below the $0.84 closing price on October 15, 2025, is a common feature in inducement agreements designed to encourage immediate warrant exercise and secure capital. This pricing strategy is often seen in growth-stage companies, particularly in the biotech sector, that need to raise funds efficiently, though it does come at the cost of dilution for existing shareholders.
• The engagement of a financial advisor (A.G.P./Alliance Global Partners LP) and a proxy solicitation firm (D.F. King & Co., Inc.) for managing complex capital raises and shareholder meetings is standard practice across public companies, reflecting the specialized expertise required for such transactions.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for significant dilution (over 35% of current outstanding shares) and potential adverse impact on stock price due to the issuance of new shares. However, approval could provide necessary capital for company operations.
• Institutional Investors (Warrant Holders): Will be able to exercise New Warrants and potentially realize gains if the stock price rises above the $0.54 exercise price, provided stockholder approval is obtained.
• Company Operations: Approval of the warrant exercise could provide up to $8.7 million in gross proceeds, which is crucial for funding the company's ongoing research, clinical development, and general operations.

Next Steps

• Hold the Special Meeting of Stockholders on April 9, 2026, to vote on the Warrant Exercise Proposal and the Adjournment Proposal.
• If the Warrant Exercise Proposal is not approved, the company is obligated to call a meeting every sixty days thereafter to seek approval until it is obtained or the New Warrants are no longer outstanding.
• The New Warrants will become exercisable commencing on the effective date of stockholder approval.

Key Dates

Recommendation

While the potential capital raise of $8.7 million is positive for funding operations, the significant dilution (over 35% of current outstanding shares) and the company's repeated failure to secure shareholder quorum for this approval present considerable uncertainty and downside risk. The discounted exercise price further weighs on existing shareholder value. Investors should hold, awaiting the outcome of the vote and further clarity on the company's ability to execute its financing strategy and manage shareholder relations.

Keywords

Theriva Biologics, TOVX, proxy statement, special meeting, warrant exercise, private placement, shareholder approval, dilution, capital raise, NYSE American, corporate governance